CAP TODAY Pathology/Laboratory Medicine/Laboratory Management
April 2, 2020—Beckman Coulter announced it is developing assays to identify IgM and IgG antibodies to SARS-CoV-2. The assays will be designed for use on any of the company’s high-throughput Access family of immunoassay systems.
“Antibody assays play a critical role in understanding the measure of immunity an individual has developed against SARS-CoV-2,” Kathleen Orland, senior vice president and general manager for Beckman Coulter’s chemistry and immunoassay business, said in a press release. “This type of understanding could help determine the identification of those who would require a vaccine once available or when an infected individual could safely return to work.”
Pages: 1 2